An interventional study of SRS and metastasectomy: surgical resection in Brain Neoplasms, Neoplasm Metastasis and Radiosurgery, sponsored by Fundacion Miguel Servet. Recruiting at 5 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Fundacion Miguel Servet · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Brain Neoplasms with a site in Spain — 13 open to participants now, 26 under way, 4 of them phase 3. Brain Neoplasms · Spain.
Among the 68 studies in Brain Neoplasms with a site in Spain, this one is the 41st largest by planned enrollment of the 63 interventional ones that give a count, is one of 4 that started in 2026, is one of 4 with no phase, reaches primary completion later than 24 of the 25 other live ones, and was the 68th registered.
2,443 studies on the registry are indexed under Brain Neoplasms; 545 are open to participants now.
Browse Brain Neoplasms studies →13 of the 68 studies in Brain Neoplasms with a site in Spain are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Spain, United States, Belgium and 10 more countries
Ages 18+
MedSIR · Sites in Spain, Austria, Germany
Ages 18+
Grupo Español Multidisciplinar de Melanoma · Sites in Spain
Ages 18+
Iambic Therapeutics, Inc · Sites in Spain, United States, France and 5 more countries
Ages 18+
Hospital San Carlos, Madrid · Sites in Spain
Ages 18–75
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 41 · Phase 3 16
First in 1996; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is above the median of 40 across 1,834 interventional studies indexed under Brain Neoplasms.
Median enrollment 72 across the 63 interventional studies, 125 across the 5 observational. Of the 40 that completed or were terminated, 25 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 68 have an industry lead sponsor. The 10 most frequent:
Fundacion Miguel Servet is the lead sponsor of 49 studies on the registry; 22 are open to participants now.
Fundacion Miguel Servet has 1 study filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
10 of the studies in Brain Neoplasms with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02066220Phase 3Universitätsklinikum Hamburg-EppendorfInternational Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma | 2026-12 |
| NCT06048718MedSIRT-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases | 2026-11 |
| NCT06418113Hospital San Carlos, MadridNeoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma | 2026-11-21 |
| NCT07558395Institut National de la Santé Et de la Recherche Médicale, FranceEffectiveness of a Visual Telerehabilitation Program on Visual Perception in Children, Adolescents and Young Adults With Hemianopsia Consecutive to a Brain Tumour | 2026-12 |
| NCT05386108Stemline Therapeutics, Inc.Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | 2026-12 |
Add all 10 to your calendar (.ics) → With an account.
Among the 68 studies in Brain Neoplasms with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The PREOP-RAD study aims to evaluate the feasibility, safety, and efficacy of preoperative surgical resection (SRS) in patients with large brain metastases requiring surgical resection, taking into account potential differences based on sex/gender, compared to postoperative SRS, within the Spanish healthcare context.
More specifically, the study seeks to:
PREOP-RAD is a prospective, randomized, multicenter study that will include patients diagnosed with symptomatic, single or multiple brain metastases ≥2 cm who are candidates for surgical resection. The procedure will consist of preoperative administration of SRS (1-5 fractions, depending on location and size), followed by surgery within a maximum of 10 days.
The intervention will be carried out in coordination with the Neurosurgery and Radiation Oncology Departments of each participating center, using a standardized workflow. The collection of surgical samples will allow for centralized histopathological studies. Furthermore, pre- and postoperative images will undergo radiomic analysis using artificial intelligence tools to explore similarities and correlate morphological and textural characteristics with clinical outcomes.
Preoperative SRS has emerged as a promising alternative. Administered before surgery, it allows for more precise planning, less exposure of healthy tissue, avoids delays due to surgical complications, and reduces the risk of neuromuscular dysfunction (nMD) by eliminating prior tumor manipulation. Recent retrospective studies and meta-analyses show local control rates similar to postoperative SRS, with a lower incidence of radionecrosis (1.5% vs. 14.6%) and nMD (3% vs. 17%). However, most of this data comes from North American centers, and prospective studies evaluating this strategy within the Spanish healthcare system, and especially its differentiated impact on patients by sex, are lacking.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
preoperative radiosurgery (SRS) in patients with brain metastases who are candidates for surgery
Radiation: SRS · Procedure: metastasectomy: surgical resection
standard treatment, consisting of surgical resection followed by irradiation of the tumor bed
Radiation: SRS · Procedure: metastasectomy: surgical resection
radiosurgery (SRS) in patients with brain metastases who are candidates for surgery
Also known as: radiosurgery
Microsurgical resection of the target brain metastasis, performed either after preoperative SRS or before postoperative SRS depending on treatment arm
Locoregional adverse event-free survival
A side effect or complication occurring specifically in the region or site where a medical procedure or treatment-such as surgery or radiotherapy-was performed.
Time frame: From randomization to the first locoregional adverse event, assessed up to 12 months after randomization
Meningeal Failure Rate
Proportion of patients developing nodular meningeal disease (nMD) during follow-up, as determined by clinical assessment and brain magnetic resonance imaging (MRI).
Time frame: 6 and 12 months after randomization.
Symptomatic Radiation Necrosis Rate
Proportion of patients developing symptomatic radiation necrosis confirmed by clinical and radiological evaluation.
Time frame: 6 and 12 months after randomization.
Local Control Rate
Proportion of patients without local recurrence at the treated lesion or surgical cavity, as assessed by brain MRI.
Time frame: 6 and 12 months after randomization.
Distant Brain Failure-Free Survival
Time from randomization to the occurrence of distant intracranial failure, defined as the appearance of new brain metastases outside the treated lesion(s).
Time frame: 6 and 12 months after randomization.
Overall Survival
Time from randomization to death from any cause.
Time frame: 6 and 12 months after randomization.
Time to Whole-Brain Radiotherapy (WBRT)
Time from randomization to the administration of whole-brain radiotherapy (WBRT).
Time frame: From randomization until administration of WBRT, up to 42 months.
Health-Related Quality of Life
Change from baseline in health-related quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Brain Neoplasm 20 (EORTC QLQ-BN20). The questionnaire includes 20 items organized into 4 disease-specific symptom scales (future uncertainty, visual disorder, motor dysfunction, communication deficit) and 7 single items. All scores are linearly transformed to a scale from 0 to 100, where a higher score represents a higher level of symptoms or worse outcome (greater symptom burden).
Time frame: Baseline, and at 3, 6, 12, 18, and 24 months after treatment.
Length of Hospital Stay
Duration of hospital stay measured in days, defined as the time from the date of hospital admission for the surgical procedure until the date of hospital discharge.
Time frame: From the date of admission for the surgical procedure until the date of hospital discharge, assessed up to 30 days.
Treatment Delay
Time elapsed between the protocol-defined optimal treatment schedule and the actual administration of treatment.
Time frame: From treatment planning to treatment completion, up to 42 months.
Started Sep 2026 (actual). Primary completion is estimated for Mar 2030, 42 months after the start.
Of 308 non-industry interventional studies with no phase under Brain Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 42 months is below that.
Counting every sponsor, half of 319 studies reached it within 64 months; a quarter within 35 and three quarters within 125.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundacion Miguel Servet